<DOC>
	<DOCNO>NCT00910104</DOCNO>
	<brief_summary>The purpose study determine whether Omegaven effective treatment parenteral nutrition associate liver disease ( PNALD ) .</brief_summary>
	<brief_title>Cholestasis Reversal : Efficacy IV Fish Oil</brief_title>
	<detailed_description>The purpose study determine whether omega-3 fatty acid emulsion ( Omegaven ) , use lieu conventional soy-based fat emulsion ( Intralipid ) , effective treatment parenteral nutrition associate liver disease ( PNALD ) .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Short Bowel Syndrome</mesh_term>
	<criteria>1 . Patients PN dependent ( unable meet nutritional need solely enteral nutrition ) expect require PN least another 30 day 2 . Patients consider eligible study participation must parenteral nutrition associate liver disease ( PNALD ) define direct bilirubin U &gt; U 2 mg/dl currently Omegaven another protocol . Other cause liver disease exclude . A liver biopsy necessary treatment . 3 . Direct bilirubin &gt; 2.0 mg/dl already Omegaven another protocol 4 . Signed patient inform consent . 5 . The patient must utilize standard therapy prevent progression his/her liver disease include surgical treatment , cyclic PN , avoid overfeeding , reduction/removal copper manganese PN , advancement enteral feeding , use ursodiol ( i..e. , ActigallÂ® ) . 1 . Pregnancy 2 . Other cause chronic liver disease ( Hepatitis C , biliary atresia , alpha 1 antitrypsin deficiency , ) 3 . Enrollment clinical trial involve investigational agent ( unless approve designated physician multidisciplinary team ) 4 . The parent guardian child unwilling provide consent assent In rare instance , patient diagnose PNALD may later find liver disease due cause addition use PN ( i.e. , inborn error metabolism , viral infection ) . Such cause may know time enrollment preclude continue study . For sake statistical analysis , however , patient exclude although data collect reviewed .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>PNALD</keyword>
	<keyword>Omegaven</keyword>
	<keyword>Parenteral Nutrition Associated Liver Disease</keyword>
	<keyword>Cholestasis</keyword>
	<keyword>Short Bowel Syndrome</keyword>
</DOC>